Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

BACKGROUND: Bimatoprost ophthalmic solution 0.03% was approved in the US for reducing intraoccular pressure (IOP) based on two double-masked, active-controlled clinical trials. Four additional long-term studies (≥12 months) were conducted; however, the aggregate safety profile of the six studies has...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirta, David, VanDenburgh, Amanda M, Weng, Emily, Whitcup, Scott M, Kurstjens, Sef, Beddingfield, Frederick C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116800/
https://www.ncbi.nlm.nih.gov/pubmed/21691584
http://dx.doi.org/10.2147/OPTH.S17457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116800/
https://www.ncbi.nlm.nih.gov/pubmed/21691584
http://dx.doi.org/10.2147/OPTH.S17457

Ejemplares similares